The Role of Salvage High-Dose Chemotherapy in Relapsed Male Germ Cell Tumors

Christoph Oing; Anja Lorch

doi:10.1159/000489135

The Role of Salvage High-Dose Chemotherapy in Relapsed Male Germ Cell Tumors

Standard

The Role of Salvage High-Dose Chemotherapy in Relapsed Male Germ Cell Tumors. / Oing, Christoph; Lorch, Anja.

In: ONCOL RES TREAT, Vol. 41, No. 6, 2018, p. 365-369.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Oing, C & Lorch, A 2018, 'The Role of Salvage High-Dose Chemotherapy in Relapsed Male Germ Cell Tumors', ONCOL RES TREAT, vol. 41, no. 6, pp. 365-369. https://doi.org/10.1159/000489135

APA

Oing, C., & Lorch, A. (2018). The Role of Salvage High-Dose Chemotherapy in Relapsed Male Germ Cell Tumors. ONCOL RES TREAT, 41(6), 365-369. https://doi.org/10.1159/000489135

Vancouver

Oing C, Lorch A. The Role of Salvage High-Dose Chemotherapy in Relapsed Male Germ Cell Tumors. ONCOL RES TREAT. 2018;41(6):365-369. https://doi.org/10.1159/000489135

Bibtex

@article{19d33211c75f46029ae8b5c42f5b481c,

title = "The Role of Salvage High-Dose Chemotherapy in Relapsed Male Germ Cell Tumors",

abstract = "Germ cell tumors (GCT) are a unique tumor entity with excellent cure rates if guideline-endorsed treatment is thoroughly applied. Even patients with widespread metastatic disease can often be cured with cisplatin-based combination chemotherapy as part of a multimodal treatment approach. However, about 30% of patients with metastatic disease at initial presentation, corresponding to about 5-10% of all GCT patients, relapse or progress despite first-line treatment and therefore require salvage chemotherapy. Salvage systemic treatment either consists of conventional-dose cisplatin-based combination chemotherapy or sequential high-dose treatment with carboplatin and etoposide plus subsequent autologous stem cell support. This review is based on a comprehensive literature search of MEDLINE and conference proceedings of ESMO, ASCO, and EAU meetings until 2018 and provides an overview of current treatment options for germ cell cancer patients relapsing after or progressing during first-line cisplatin-based combination chemotherapy.",

keywords = "Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Cisplatin/administration & dosage, Dose-Response Relationship, Drug, Hematopoietic Stem Cell Transplantation/methods, Humans, Male, Neoplasm Recurrence, Local, Neoplasms, Germ Cell and Embryonal/drug therapy, Salvage Therapy/methods, Testicular Neoplasms/drug therapy",

author = "Christoph Oing and Anja Lorch",

note = "{\textcopyright} 2018 S. Karger GmbH, Freiburg.",

year = "2018",

doi = "10.1159/000489135",

language = "English",

volume = "41",

pages = "365--369",

journal = "ONCOL RES TREAT",

issn = "2296-5270",

publisher = "S. Karger AG",

number = "6",

}

RIS

TY - JOUR

T1 - The Role of Salvage High-Dose Chemotherapy in Relapsed Male Germ Cell Tumors

AU - Oing, Christoph

AU - Lorch, Anja

PY - 2018

Y1 - 2018

N2 - Germ cell tumors (GCT) are a unique tumor entity with excellent cure rates if guideline-endorsed treatment is thoroughly applied. Even patients with widespread metastatic disease can often be cured with cisplatin-based combination chemotherapy as part of a multimodal treatment approach. However, about 30% of patients with metastatic disease at initial presentation, corresponding to about 5-10% of all GCT patients, relapse or progress despite first-line treatment and therefore require salvage chemotherapy. Salvage systemic treatment either consists of conventional-dose cisplatin-based combination chemotherapy or sequential high-dose treatment with carboplatin and etoposide plus subsequent autologous stem cell support. This review is based on a comprehensive literature search of MEDLINE and conference proceedings of ESMO, ASCO, and EAU meetings until 2018 and provides an overview of current treatment options for germ cell cancer patients relapsing after or progressing during first-line cisplatin-based combination chemotherapy.

AB - Germ cell tumors (GCT) are a unique tumor entity with excellent cure rates if guideline-endorsed treatment is thoroughly applied. Even patients with widespread metastatic disease can often be cured with cisplatin-based combination chemotherapy as part of a multimodal treatment approach. However, about 30% of patients with metastatic disease at initial presentation, corresponding to about 5-10% of all GCT patients, relapse or progress despite first-line treatment and therefore require salvage chemotherapy. Salvage systemic treatment either consists of conventional-dose cisplatin-based combination chemotherapy or sequential high-dose treatment with carboplatin and etoposide plus subsequent autologous stem cell support. This review is based on a comprehensive literature search of MEDLINE and conference proceedings of ESMO, ASCO, and EAU meetings until 2018 and provides an overview of current treatment options for germ cell cancer patients relapsing after or progressing during first-line cisplatin-based combination chemotherapy.

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Cisplatin/administration & dosage

KW - Dose-Response Relationship, Drug

KW - Hematopoietic Stem Cell Transplantation/methods

KW - Humans

KW - Male

KW - Neoplasm Recurrence, Local

KW - Neoplasms, Germ Cell and Embryonal/drug therapy

KW - Salvage Therapy/methods

KW - Testicular Neoplasms/drug therapy

U2 - 10.1159/000489135

DO - 10.1159/000489135

M3 - SCORING: Review article

C2 - 29843143

VL - 41

SP - 365

EP - 369

JO - ONCOL RES TREAT

JF - ONCOL RES TREAT

SN - 2296-5270

IS - 6

ER -